New agreements with Eli Lilly and Novo Nordisk are set to dramatically lower the cost of popular weight-loss drugs, making them accessible to millions through Medicare. This creates an investment opportunity centered on the major pharmaceutical companies involved and the broader supply chain that will support the expected surge in demand.
11์ 8 ๊ฒ์
Medicare's first-ever coverage of weight-loss drugs represents a landmark shift that could unlock demand from millions of previously underserved patients.
From manufacturers to distributors to pharmacies, the entire healthcare supply chain is positioned to benefit from the anticipated surge in prescription volume.
With proven market demand now backed by insurance coverage, biotech companies are racing to develop next-generation oral alternatives and improved delivery methods.
Recent Medicare agreements with major pharmaceutical companies like Eli Lilly and Novo Nordisk are making popular weight-loss drugs more affordable and accessible. This policy shift creates a significant investment opportunity as millions of new patients gain access to GLP-1 medications, potentially driving substantial revenue growth across the entire healthcare supply chain.
This group focuses on companies positioned to benefit from increased demand for weight-loss medications. It includes primary drug manufacturers, innovative biotechnology companies developing next-generation treatments, and essential supply chain partners like distributors and pharmacy retailers. The theme captures both immediate beneficiaries and long-term growth opportunities in this expanding market.
These stocks were handpicked by professional analysts based on their strategic positioning within the weight-loss drug ecosystem. From established pharmaceutical giants to innovative biotech companies developing oral alternatives, each represents a different way to benefit from the expected surge in demand following Medicare's landmark coverage expansion.
Market capitalisation breakdown and investor key points for the basket named 'Medicare's Weight Loss Drug Deal'.
LLY: $873.88B
NVO: $152.67B
VRTX: $103.89B
์ด ๋ฐ์ค์ผ์ ์ ์ฒด ์คํ ๋ฆฌ๋ฅผ ํ์ธํ์ธ์. ๋ฆฌ์คํฌ์ ์ ์ฌ๋ ฅ์ ๋ค๋ฃฌ ์์ธ ๊ธฐ์ฌ๋ฅผ ์ฝ์ด๋ณด์ธ์.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly & Co
LLY
ํ์ฌ๊ฐ
$1,115.23
A primary manufacturer of popular GLP-1 drugs like Mounjaro and Zepbound, making it central to the theme of expanding access to weight-loss medication...
A primary manufacturer of popular GLP-1 drugs like Mounjaro and Zepbound, making it central to the theme of expanding access to weight-loss medications.
VERTEX PHARMACEUTICAL
VRTX
ํ์ฌ๊ฐ
$515.44
A major biotechnology company with a robust pipeline, positioned to innovate and compete in the expanding market for metabolic and weight-loss therapi...
A major biotechnology company with a robust pipeline, positioned to innovate and compete in the expanding market for metabolic and weight-loss therapies.
Join Nemo FREE today and unlock every stock
60์ด๋ฉด ์ถฉ๋ถํฉ๋๋ค.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitiv Ltd.
์ด ์์ฐ๋ค์ ํฌ์ํ๋ค๋ฉด:
12๊ฐ์ ํ ์์ ๊ฐ์น:
+228.92%
์ ๋๋ฆฌ์คํธ๋ค์ ์ด ๊ทธ๋ฃน์ ์์ฐ์ด ํฅํ 1๋ ๊ฐ ํ๊ท 228.92% ์ฑ์ฅํ ๊ฒ์ผ๋ก ์์ํฉ๋๋ค.
์ด ๊ทธ๋ฃน์ ์์ฐ 15๊ฐ ์ค 12๊ฐ๊ฐ ์ ๋ฌธ ์ ๋๋ฆฌ์คํธ๋ก๋ถํฐ ๋งค์ ์๊ฒฌ์ ๋ฐ์์ต๋๋ค.
